{"entity":{"id":"vnx-101","kind":"drug","name":"VNX-101","aka":["AAV.CD3/CD19"],"tldr":"VNX-101 is an experimental in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics, in phase 1 trials for CD19-positive B-cell acute lymphoblastic leukaemia, B-cell lymphomas and chronic lymphocytic leukaemia.","summary":"VNX-101 (AAV.CD3/CD19) is an in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics. A single intravenous dose of an adeno-associated virus vector that makes the liver secrete a CD3 x CD19 bispecific T-cell engager continuously. Its furthest stage is phase 1, for CD19-positive B-cell acute lymphoblastic leukaemia, B-cell lymphomas (large B-cell, follicular, mantle cell, marginal zone, Burkitt) and chronic lymphocytic leukaemia. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 SENTRY-CD19 NCT06533579 recruiting. The company lists FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Vironexis Biotherapeutics: vironexis.com","url":"https://vironexis.com"},{"label":"Vironexis Biotherapeutics: vironexis.com","url":"https://vironexis.com"},{"label":"Vironexis Biotherapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06533579"},{"label":"ClinicalTrials.gov: trials of VNX-101","url":"https://clinicaltrials.gov/search?intr=VNX-101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia","non-hodgkin-lymphoma","cll"],"sections":[],"technologies":[],"targets":["cd19","cd3"],"drugs":[],"companies":["vironexis-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06533579"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"VNX-101","modality":"In vivo gene therapy: AAV vector encoding a bispecific T-cell engager","mechanism":"A single intravenous dose of an adeno-associated virus vector that makes the liver secrete a CD3 x CD19 bispecific T-cell engager continuously.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vnx-101/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"company":[{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","route":"/companies/vironexis-biotherapeutics/"}],"trial":[{"id":"nct06533579","kind":"trial","name":"Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","route":"/trials/nct06533579/"}]}}